Current tools for measuring medication adherence have significant limitations, especially among pediatric populations. We conducted a prospective observational study to assess the use of antiretroviral (ARV) drug levels in hair for evaluating antiretroviral therapy (ART) adherence among HIV-infected children in rural Uganda. Three-day caregiver recall, 30-day visual analog scale (VAS), Medication Event Monitoring System (MEMS), and unannounced pill counts and liquid formulation weights (UPC) were collected monthly over a one-year period. Hair samples were collected quarterly and analyzed for nevirapine (NVP) levels, and plasma HIV RNA levels were collected every six months. Among children with at least one hair sample collected, we used univariable random intercept linear regression models to compare log transformed NVP concentrations with each adherence measure, and the child's age, sex, and CD4 count percentage (CD4%). One hundred and twenty-one children aged 2-10 years were enrolled in the study; 74 (61%) provided at least one hair sample, and the mean number of hair samples collected per child was 1.9 (standard deviation [SD] 1.0). Three-day caregiver recall, VAS, and MEMS were found to be positively associated with increasing NVP concentration in hair, although associations were not statistically significant. UPC was found to have a nonsignificant negative association with increasing hair NVP concentration. In conclusion, NVP drug concentrations in hair were found to have nonsignificant, although generally positive, associations with other adherence measures in a cohort of HIVinfected children in Uganda. Hair collection in this population proved challenging, suggesting the need for community education and buy-in with the introduction of novel methodologies.
Introduction
In 2012, an estimated 2.9 million children under age 15 were living with HIV in sub-Saharan Africa, of whom 544,000 were receiving antiretroviral therapy (ART; WHO, 2013) . While some studies report generally high adherence to ART (Barro et al., 2011; Haberer et al., 2011) , others are as low as 49% (Vreeman, Wiehe, Pearce, & Nyandiko, 2008) . Even in the studies with high adherence, low rates of viral suppression and the presence of drug resistance suggest current adherence assessments may be incorrect and/or important adherence challenges exist (Ahoua et al., 2011; Barro et al., 2011; Barth et al., 2011; Dehority, Deville, Lujan-Zilbermann, Spector, & Viani, 2013; Orrell et al., 2013) . Accurate, reliable, and practical means of evaluating pediatric ART adherence are critical in overcoming these concerns.
Multiple approaches exist for measuring ART adherence (Berg & Arnsten, 2006) ; however, all have significant limitations. Self-report of adherence typically overestimates adherence (Bhattacharya & Dubey, 2011; Biressaw, Abegaz, Abebe, Taye, & Belay, 2013; Martin et al., 2009; Naar-King, Frey, Harris, & Arfken, 2005) , as it may be influenced by social desirability and recall biases (Kagee & Nel, 2012) . Clinic-based pill counts may be inaccurate if children or caregivers remove extra medication to appear more adherent (Simoni et al., 2006) . Moreover, patients may not remember to bring their medication to appointments (Mghamba, Minzi, Massawe, & Sasi, 2013) . Electronic adherence monitoring (e.g., Medication Event Monitoring System [MEMS]; Haberer, Kahane, et al., 2010; Haberer, Kiwanuka, Nansera, Wilson, & Bangsberg, 2010) is costly, and bottle openings do not always reflect medication ingestion (Martin et al., 2009 ). Finally, plasma antiretroviral (ARV) drug levels reflect only short-term adherence (1-3 days; Nettles et al., 2006; Wertheimer, Freedberg, Walensky, Yazdanapah, & Losina, 2006) , adherence may transiently improve before clinic visits (Cramer, Scheyer, & Mattson, 1990; Podsadecki, Vrijens, Tousset, Rode, & Hanna, 2008) , and collection is resourceintensive, requiring cold chain and phlebotomy (ter Heine, Beijnen, & Huitema, 2009 ). These limitations highlight the need for alternative feasible, acceptable, and valid adherence measures.
Measuring ARV drug levels in hair is a promising approach for evaluating ART adherence in developing settings (Beumer, Bosman, & Maes, 2001; Gandhi, Yang, Bacchetti, & Huang, 2014; Hickey et al., 2014; Huang et al., 2008; Huang et al., 2011) . Hair samples are simple to collect, can be stored at room temperature, and are processed without biohazardous precautions. Hair concentrations of ARVs reflect uptake from systemic circulation over weeks to months and have been shown to correlate well with plasma drug levels (van Zyl et al., 2011) and viral suppression (Bernard, Peytavin, Vuagnat, de Truchis, & Perronne, 1998; Bernard et al., 2002; Duval et al., 2007; Gandhi et al., 2011; Gandhi et al., 2009; Servais et al., 2001; van Zyl et al., 2011) .
In this study, we sought to assess the use of ARV drug levels in hair samples from HIV-infected children in rural Uganda for evaluating ART adherence through correlation with other adherence measures.
Methods

Study population
Between July 2008 and February 2009, HIV-infected children aged 2-10 years were recruited into a longitudinal observational cohort study (NCT00868257) from the Children's HIV/AIDS Care Clinic in Mbarara, Uganda. Participants included children initiating and those established on ART. Both liquid and pill formulations were used; prescriptions reflected World Health Organization guidelines (e.g., nevirapine [NVP]: 160-200 mg/m 2 to max 200 mg twice daily) (WHO, 2010) . The clinic provides ARVs free of charge.
Data collection
This report describes an analysis of data collected in a previously published cohort study (Haberer et al., 2012) . Briefly, in the cohort study, adherence was monitored monthly for one year using caregiver interview for threeday recall (Usitalo et al., 2014) , and 30-day visual analog scale (VAS; Amico et al., 2006) , MEMS (Haberer et al., 2011) , and unannounced pill counts and liquid formulation weights (UPC; Farley et al., 2008) . Hair samples were collected quarterly. Plasma HIV RNA levels were assessed at baseline, 6, and 12 months (Roche Amplicor HIV-1 Monitor Test, USA). Hair samples were also collected quarterly as a novel adherence measure but were not included in the initial publication due to delays in sample processing.
Hair collection and ARV concentration determination
Research assistants cut or shaved a small thatch of hair as close as possible to the occipital scalp. Methods for extraction and analyses of ARV drug concentration in hair are reported elsewhere (Huang et al., 2008; Huang et al., 2011) . Drug levels were determined only for children taking NVP-based regimens, as they comprised the majority of the cohort (77% of those providing hair samples). Our methods have been validated from 0.50 to 200 nanograms (ng)/milligrams (mg) hair for NVP with good linearity (R 2 > 0.99) and reproducibility (coefficient of variation [CV] <10%).
Statistical analysis
Sample size was determined by the parent study as described previously (Haberer et al., 2012) . Descriptive statistics were used to explore the child's characteristics, number of hair samples collected, summary drug concentrations, and adherence measures (reflecting the three months before hair collection). Adherence measures were not capped at 100% to avoid potential introduction of bias; however, MEMS data were treated as missing in cases of known or suspected (e.g., >30 days with no openings) device nonuse.
Among children with at least one hair sample collected, we used univariable random intercept linear regression models (SAS proc mixed) to model NVP hair concentrations in terms of each adherence measure, as well as the child's age, sex, and CD4 count percentage (CD4%). Drug concentrations were log-transformed. The association of variables with loss of viral suppression was not assessed as this event only occurred in four children.
Ethics statement
The study was approved by the Mbarara University of Science and Technology (MUST) Research Ethics Committee, Mbarara, Uganda, and the Partners Health Care Human Research Committee, Boston, MA. We received clearance from the Uganda National Council on Science and Technology, and a materials transfer agreement to ship hair samples to the University of California San Francisco (UCSF) for processing was ratified by UCSF and MUST. Caregivers provided written informed consent, and children provided verbal assent when possible (typically those aged seven years and older).
Results
Participant characteristics
A total of 121 HIV-infected children were enrolled in the cohort study; 74 (61%) provided at least one hair sample, and 61 (82%) of the 74 were on NVP regimens. For those 61 participants, the median age was 4.7 years (IQR 1.2-8.2), and 51% were female. Their median CD4% was 44.5 (IQR 25.5-63.5), and median weight was 17.0 kg . Of these children on NVP, 39 (64%) were established on ART, and 22 (36%) were on liquid formulations. Quarterly hair collection was as follows: 23 (16%) in Q1, 37 (26%) in Q2, 40 (28%) in Q3, and 27 (19%) in Q4; 17 (12%) were missing the collection date and were excluded from the statistical analysis.
Hair collection
A total of 144 quarterly hair samples were collected, with a mean of 1.9 (standard deviation [SD] 1.0) among those who provided at least one sample.
Adherence measures
For the three-month time period prior to each collected hair sample in the children taking NVP-based ART (N = 61), median and mean adherence as assessed by each measure and are listed in Table 1 . Median and mean NVP hair concentrations were 76.7 ng/mg of hair (IQR 27.7-125.7) and 104.4 ng/mg (SD 109.3), respectively. No data were available for the three-month time period in 6.6% of three-day caregiver reports, 7.2% of 30-day VAS, 9.7% of MEMS, and 11.4% of UPC. Figure 1 shows scatterplots of each adherence measure versus NVP hair concentration. Three-day caregiver recall, VAS, and MEMS were positively associated with increasing NVP concentration in hair, although not statistically significant (Table 1) . UPC was found to have a nonsignificant negative association with increasing hair NVP concentration.
Comparison of adherence measures and NVP hair concentration
Discussion
In this study, we compared NVP concentration in pediatric hair samples with multiple measures of adherence (Haberer et al., 2012) . We found positive associations with all the measures of adherence aside from UPC, with proportionally or greater than proportionally higher hair levels with higher adherence, although there was substantial variability in hair levels within the same reported adherence level (Figure 1 ) and none of these associations reached statistical significance. Similar positive associations between NVP concentration and self-reported adherence were seen in a study among Kenyan adults (Hickey et al., 2014) . The negative association with UPC is difficult to interpret. Midway through the study, we learned that clinic pharmacists were taking back and giving out extra medication in efforts to facilitate adherence among patients; this practice may have limited UPC accuracy. Liquid weight measurements may also have been inaccurate. NVP hair concentrations in this study were in the range of those in another Africa-based study (Hickey et al., 2014) .
In contrast to previous studies conducted by our research group showing high acceptability and feasibility of collecting hair samples in developing settings (Bartelink et al., 2013; Baxi, 2014; Gandhi et al., 2013; Hickey et al., 2014; van Zyl et al., 2011) , we found collection challenging among HIV-infected children in rural Uganda. Though we attempted to collect four samples per child, only 144 (30% of 484 samples) were obtained with a mean of 1.9 per child among the 61% who provided any samples. Participants readily provided data for other adherence measures, but hair collection was commonly declined or the child's head was already clean-shaven.
While we did not design the study to elucidate hair sample refusal, we hypothesize that primary barriers were traditional practices and preference. In Uganda, caregivers shave children's heads for reasons related to hygiene, difficulty in combing, local custom, and preference. When planning the study, we informally asked Ugandan research colleagues about appropriate frequency for hair collection and decided on quarterly collection. However, children often had no hair at the time of collection, and we learned caregivers shaved their children's heads as often as monthly. Additionally, HIV-infected children and caregivers face significant stigma and discrimination (Amzel et al., 2013) ; alteration of head-shaving practices could have led to fear of unintended HIV status disclosure or having the child viewed as "different." 
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Prior research on pediatric ARV drug levels in hair is limited to one study on ARV transfer from mother to infant (Gandhi et al., 2013) and another assessing ART adherence among a pediatric cohort in Asia (Prasitsuebsai et al., 2013) . In the latter study, acceptability of hair collection was high (90%) and a strong association between hair lopinavir levels and virologic outcomes was observed. Unlike the current study, community education and buy-in was obtained and may at least partially explain differences in feasibility. Community mobilization is integral to implementing HIV-related interventions (Kawichai et al., 2012; Tedrow et al., 2012) and likely applies to introducing research methods.
Despite the challenges encountered in this study, the use of ARV drug concentrations in hair as an adherence measure shows promise for children in developing settings. The relationships with other adherence measures should be explored in a larger sample with high baseline virologic suppression rates. Further research should also explore the costs associated with hair sample testing in resource-limited settings, as well as involve community mobilization and dedicated assessment of potential barriers and solutions for hair sample collection. 
